Sbf Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.21 Cr
as on 16-11-2024
- Company Age 13 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 2.14 Cr
as on 16-11-2024
- Revenue 5.86%
(FY 2023)
- Profit 139.19%
(FY 2023)
- Ebitda 90.84%
(FY 2023)
- Net Worth 1.28%
(FY 2023)
- Total Assets 11.51%
(FY 2023)
About Sbf Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.21 Cr.
The company has closed loans amounting to ₹2.14 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Rushil Barot and Sanjay Barot serve as directors at the Company.
- CIN/LLPIN
U24230GJ2011PTC064654
- Company No.
064654
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Mar 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Gandhi Nagar, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Sbf Pharma Private Limited offer?
Sbf Pharma Private Limited offers a wide range of products and services, including Chemical Reagents & Catalysts, Inorganic Salts, Pharma Ingredients & Raw Materials, Vitamin Powder API, Industrial Chemicals & Supplies, Electroplating Chemicals, Coir and Agro Products, Natural Gum, API (Active Pharmaceutical Ingredients), Bird Food, Poultry & Animal Food.
Who are the key members and board of directors at Sbf Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rushil Barot  | Director | 28-Mar-2011 | Current |
| Sanjay Barot | Director | 28-Mar-2011 | Current |
Financial Performance of Sbf Pharma.
Sbf Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.86% increase. The company also saw a substantial improvement in profitability, with a 139.19% increase in profit. The company's net worth moved up by a moderate rise of 1.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sbf Pharma?
In 2023, Sbf Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Corporation Bank Creation Date: 18 Jan 2013 | ₹2.14 Cr | Satisfied |
How Many Employees Work at Sbf Pharma?
Unlock and access historical data on people associated with Sbf Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sbf Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sbf Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
